Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement Regulation, Fibrosis, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VTN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VTN Full-Length / Domain-Specific Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed (Native Glycosylation). | View VTN Products |
| Gene Delivery | VTN Premade Lentivirus Particles / Promise-ORF. Full-length ORF for stable cell line construction in adhesion/complement assays. | View VTN Products |
| Benchmark Ab | Anti-VTN Neutralizing Antibody (Chimeric/Humanized). Recombinant positive control for domain-blocking studies. | View VTN Products |
| Validator | VTN siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View VTN Products |
| Related Target: ITGAV | Integrin αV (CD51). Primary VTN receptor; essential for adhesion assay validation. | View ITGAV Products |
| Related Target: C3 | Complement C3. Complement pathway partner; VTN stabilizes C3 convertase. | View C3 Products |
| Related Target: TGFB1 | TGF-beta 1. Fibrosis pathway synergism; VTN regulates TGFB activation. | View TGFB1 Products |
| Related Target: SERPINE1 | PAI-1. Binds VTN to regulate extracellular matrix degradation and fibrinolysis. | View SERPINE1 Products |
Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-Domain Binding Complexity (Heparin-binding vs RGD vs SMB domains) | Domain-truncated variants available (SMB domain only, Hemopexin domain only) with strict Mass Spec verification. |
| Cross-species Cyno/Mouse Preclinical Evaluation | Human/Mouse/Cyno VTN ortholog proteins available with >95% purity; sequence identity mapped for epitope conservation. |
| Serum Stability & Competition Assays | Endotoxin-controlled (<0.1 EU/ug) critical for complement pathway assays; Heparin-binding competent conformation. |
| False Positives in Adhesion Assays | Validated siRNA included for specificity checks; Negative control proteins (denatured VTN) available. |
| Native Glycosylation Requirement | HEK293 Expressed (Native Glycosylation) preserves integrin binding sites. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included for assay standardization. |
Live VTN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VTN-targeted therapeutics is intensifying, with major players shifting focus from broad immunosuppressants to precise complement pathway modulation and extracellular matrix (ECM) remodeling. VTN's dual role as a stabilizer of the terminal complement complex (TCC) and a key regulator of the alternative pathway positions it as a high-value target for age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and idiopathic pulmonary fibrosis (IPF). Concurrently, the next wave of R&D is targeting direct ECM modulation within the tumor microenvironment (TME) and fibrotic niches, combining VTN inhibition with immune checkpoint or anti-fibrotic agents to overcome resistance in highly fibrotic solid tumors. The current pipeline emphasizes monoclonal antibodies targeting the heparin-binding domain, peptide inhibitors blocking the SMB domain interaction with PAI-1, and bispecific molecules that simultaneously engage complement and ECM pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Domain-specific) | Early-stage biotechs, Alexion pipeline | AMD, aHUS, Glomerulonephritis | Heparin-binding Domain Binding Assay (Need high-purity VTN with native conformation) |
| Peptide Inhibitors (SMB domain) | Academic consortia, Peptide-focused biotechs | Fibrosis, Thrombosis | PAI-1 Competition Assay (Need full-length VTN with active SMB domain) |
| Small Molecule (RGD mimetics) | Oncology-focused pharma | Metastatic Cancer | Integrin αVβ3 Competition (Need Human/Mouse VTN cross-reactivity panel) |
| Bi-specific (VTN x C3) | Complement specialty biotechs | Complement-mediated diseases | TCC Formation Inhibition (Need endotoxin-controlled VTN for complement assays) |
| Gene Therapy / siRNA | Targeted delivery firms | Liver Fibrosis (NASH) | Knockdown Validation (Need Sequence Verified reagents) |